British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.
Adrenal Cortex Hormones
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ adverse effects
Antineoplastic Agents, Immunological
/ adverse effects
Consensus
Endoscopy
/ methods
Endoscopy, Digestive System
/ methods
Enterocolitis
/ chemically induced
Gastroenterology
/ organization & administration
Gastrointestinal Diseases
/ chemically induced
Guidelines as Topic
Humans
Infliximab
/ therapeutic use
Lactoferrin
/ metabolism
Leukocyte L1 Antigen Complex
/ metabolism
Neoplasms
/ drug therapy
Patient Care Management
/ methods
Societies, Medical
/ organization & administration
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
United Kingdom
/ epidemiology
Journal
The lancet. Gastroenterology & hepatology
ISSN: 2468-1253
Titre abrégé: Lancet Gastroenterol Hepatol
Pays: Netherlands
ID NLM: 101690683
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
17
11
2019
revised:
21
01
2020
accepted:
21
01
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
28
8
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.
Identifiants
pubmed: 32553146
pii: S2468-1253(20)30014-5
doi: 10.1016/S2468-1253(20)30014-5
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Leukocyte L1 Antigen Complex
0
Tumor Necrosis Factor-alpha
0
vedolizumab
9RV78Q2002
Infliximab
B72HH48FLU
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
679-697Subventions
Organisme : Medical Research Council
ID : MR/S000828/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.